 Apatinib is a tyrosin-inhibitor agent targeting at VEGFR vasoendothelial growth factor receptor to inhibit tumor angiogenesis. The anti-angiogenesis effect of apatinib has been viewed in preclinical tests see protocol. This phase I clinical study is going to evaluate its toxicity and to find an appropriate dose level to be used in a phase II study in heavily treated solid tumor patients. 